By Colin Kellaher
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Arcturus on Thursday said the designation recognizes the potential of ARCT-2304, a messenger RNA-based vaccine candidate, to address unmet medical needs for the prevention of disease caused by pandemic influenza A virus H5N1.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Arcturus, a San Diego medicines and vaccines company, in November launched a Phase 1 clinical study, supported in whole with federal funds from the Department of Health and Human Services.
Outbreaks of avian influenza A H5N1, also known as bird flu, have been decimating U.S. poultry flocks since 2022, and while the federal government currently assesses the risk from H5N1 viruses to the general U.S. population as low, it has committed hundreds of millions of dollars to push development of vaccines for a potential pandemic.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 10, 2025 08:44 ET (12:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。